CO6210815A2 - ISOQUINOLIN AND ISOQUINOLINONA DERIVATIVES REPLACED WITH CYCLLOKYLAMINE - Google Patents
ISOQUINOLIN AND ISOQUINOLINONA DERIVATIVES REPLACED WITH CYCLLOKYLAMINEInfo
- Publication number
- CO6210815A2 CO6210815A2 CO09061604A CO09061604A CO6210815A2 CO 6210815 A2 CO6210815 A2 CO 6210815A2 CO 09061604 A CO09061604 A CO 09061604A CO 09061604 A CO09061604 A CO 09061604A CO 6210815 A2 CO6210815 A2 CO 6210815A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkylene
- alkyl
- isoquinolinona
- cycllokylamine
- isoquinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Abstract
1.- Un compuesto de la fórmula (I)en la que R1 es H, OH o NH2; R2 es R´, alquilo (C7-C8), alquileno (C1-C6)-R', alquenilo (C2-C6), alquinilo (C2-C6),alquileno (C1-C6)-O-R´, alquileno (C1-C6)-CH[R´]2, alquileno (C1-C6)-C(O)-R', alquileno (C1-C6)-C(O)NH2, alquileno (C1-C6)-C(O)NH-R', alquileno (C1-C6)-C(O)NH-alquilo (C1-C6), alquileno (C1-C6)-C(O)N[alquilo (C1-C6)]2, alquileno (C1-C6)-C(O)N[R']2; alquileno (C1-C6)-C(O)O-alquilo (C1-C6), C(O)O-alquilo (C1-C6), C(O)OR', C(O)-alquilo (C1-C6), C(O)R', C(O)-NH-alquenilo (C2-C6), C(O)-NH-alquinilo (C2-C6), C(O)NH-alquilo (C1-C6), C(O)NHR', C(O)-NH-alquileno (C1-C6)-R', C(O)N[alquilo (C1-C6)]R', C(O)N[alquilo (C1-C6)]2, C(O)-alquileno (C1-C6)-R´, C(O)O-alquileno (C1-C6)-R´; o R2 es alquilo (C1-C6), con la condición de que en dicho resto alquilo al menos un hidrógeno esté sustituido con OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 o CON(CH3)2; o R2 es un alquileno (C1-C4) unido a la cicloalquilamina, donde el alquileno (C1-C4) forma un segundo enlace con un átomo de carbono diferente del anillo de cicloalquilamina y forma, junto con átomos de carbono de la cicloalquilamina, un segundo anillo de 4-8 miembros; R3 es H, halógeno, alquilo (C1-C6), ...1. A compound of the formula (I) in which R1 is H, OH or NH2; R2 is R´, (C7-C8) alkyl, (C1-C6) alkylene, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) -OR´ alkylene, (C1-) alkylene C6) -CH [R´] 2, (C1-C6) alkylene -C (O) -R ', (C1-C6) alkylene -C (O) NH2, (C1-C6) alkylene -C (O) NH -R ', (C1-C6) alkylene -C (O) NH-(C1-C6) alkyl, (C1-C6) alkylene -C (O) N [(C1-C6) alkyl] 2, (C1-) alkylene C6) -C (O) N [R '] 2; (C1-C6) alkylene -C (O) O-C1-C6 alkyl, C (O) O-C1-C6 alkyl, C (O) OR ', C (O) -C1-C6 alkyl ), C (O) R ', C (O) -NH-alkenyl (C2-C6), C (O) -NH-alkynyl (C2-C6), C (O) NH-alkyl (C1-C6), C (O) NHR ', C (O) -NH-(C1-C6) alkylene-C', C (O) N [(C1-C6) alkyl] R ', C (O) N [(C1-) alkyl C6)] 2, C (O) -C1-C6 alkylene -R´, C (O) O-C1-C6 alkylene -R´; or R2 is (C1-C6) alkyl, with the proviso that in said moiety, at least one hydrogen is substituted with OH, OCH3, COOH, COOCH3, NH2, NHCH3, N (CH3) 2, CONH2, CONHCH3 or CON ( CH3) 2; or R2 is a (C1-C4) alkylene bonded to cycloalkylamine, where (C1-C4) alkylene forms a second bond with a different carbon atom of the cycloalkylamine ring and forms, together with cycloalkylamine carbon atoms, a second ring of 4-8 members; R3 is H, halogen, (C1-C6) alkyl, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06026897 | 2006-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6210815A2 true CO6210815A2 (en) | 2010-10-20 |
Family
ID=38050127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09061604A CO6210815A2 (en) | 2006-12-27 | 2009-06-12 | ISOQUINOLIN AND ISOQUINOLINONA DERIVATIVES REPLACED WITH CYCLLOKYLAMINE |
Country Status (38)
Country | Link |
---|---|
US (1) | US8710077B2 (en) |
EP (1) | EP2102164B1 (en) |
JP (1) | JP5318779B2 (en) |
KR (1) | KR101494452B1 (en) |
CN (1) | CN101578266B (en) |
AR (1) | AR064531A1 (en) |
AT (1) | ATE490243T1 (en) |
AU (1) | AU2007338412B2 (en) |
BR (1) | BRPI0720859A2 (en) |
CA (1) | CA2673922C (en) |
CL (1) | CL2007003820A1 (en) |
CO (1) | CO6210815A2 (en) |
CR (1) | CR10811A (en) |
CY (1) | CY1111323T1 (en) |
DE (1) | DE602007010981D1 (en) |
DK (1) | DK2102164T3 (en) |
EC (1) | ECSP099468A (en) |
ES (1) | ES2355534T3 (en) |
GT (1) | GT200900183A (en) |
HK (1) | HK1138585A1 (en) |
HR (1) | HRP20100705T1 (en) |
MA (1) | MA31076B1 (en) |
MX (1) | MX2009005967A (en) |
MY (1) | MY154767A (en) |
NI (1) | NI200900111A (en) |
NO (1) | NO20092488L (en) |
NZ (1) | NZ577984A (en) |
PL (1) | PL2102164T3 (en) |
PT (1) | PT2102164E (en) |
RS (1) | RS51655B (en) |
RU (1) | RU2468011C2 (en) |
SI (1) | SI2102164T1 (en) |
SV (1) | SV2009003314A (en) |
TN (1) | TN2009000274A1 (en) |
TW (1) | TWI423803B (en) |
UY (1) | UY30845A1 (en) |
WO (1) | WO2008077556A1 (en) |
ZA (1) | ZA200903555B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008000017A (en) | 2005-06-28 | 2008-03-26 | Sanofi Aventis | Isoquinoline derivatives as inhibitors of rho-kinase. |
ES2580108T3 (en) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Isoquinoline compounds |
MX2008000956A (en) | 2005-07-26 | 2008-03-27 | Sanofi Aventis | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors. |
PT1910333E (en) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
JP5405316B2 (en) | 2006-12-27 | 2014-02-05 | サノフイ | Cycloalkylamine substituted isoquinoline derivatives |
AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
MY155009A (en) | 2006-12-27 | 2015-08-28 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
PT2102164E (en) | 2006-12-27 | 2011-01-21 | Sanofi Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
BRPI0720909A2 (en) | 2006-12-27 | 2016-11-01 | Sanofi Aventis | substituted isoquinoline and isoquinolinone derivatives |
BRPI0720862A2 (en) | 2006-12-27 | 2014-02-25 | Sanofi Aventis | ISOKINOLINE AND ISOQUINOLINONE DERIVATIVES REPLACED AS RHO-KINASE INHIBITORS |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
EP2303845B1 (en) | 2008-06-24 | 2013-09-18 | Sanofi | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
JP5713893B2 (en) | 2008-06-24 | 2015-05-07 | サノフイ | Substituted isoquinolines and isoquinolinones as Rho-kinase inhibitors |
CN102131785B (en) * | 2008-06-24 | 2014-10-29 | 赛诺菲-安万特 | 6-substituted isoquinolines and isoquinolinones |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
JP2012519732A (en) * | 2009-03-09 | 2012-08-30 | サーフェイス ロジックス,インコーポレイティド | RHO kinase inhibitor |
EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
EP2611793A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
CN103648499B (en) * | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
SG11201506800YA (en) * | 2013-03-14 | 2015-09-29 | Bristol Myers Squibb Co | Bicyclo [2.2.2] acid gpr120 modulators |
CN111793068A (en) * | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | Heteroaryl compounds and uses thereof |
EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN109528721B (en) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | Combination therapy |
PL3640241T3 (en) | 2013-10-18 | 2022-12-05 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US10189780B2 (en) | 2013-12-12 | 2019-01-29 | Zeno Royalties & Milestones, LLC | Bicyclic alkyl compounds and synthesis |
FR3017868A1 (en) | 2014-02-21 | 2015-08-28 | Servier Lab | ISOQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
CN106232567B (en) | 2014-03-07 | 2021-11-02 | 里科瑞尔姆Ip控股有限责任公司 | Propalane derivatives and synthesis |
EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
AR104259A1 (en) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | BROMODOMINUM INHIBITORS |
KR102579582B1 (en) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | Methods for Preparing Kinase Inhibitors and Intermediates Thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
WO2017160926A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
JP2019513804A (en) | 2016-04-18 | 2019-05-30 | セルジーン クオンティセル リサーチ,インク. | Therapeutic compounds |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CA3035566A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
CN110506037A (en) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | Aryl cyclopropyl-amino-isoquinolin amide compound |
CA3063729A1 (en) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2485537B2 (en) | 1977-04-13 | 1986-05-16 | Anvar | DIPYRIDO (4,3-B) (3,4-F) INDOLES, PROCESS FOR OBTAINING IT, THERAPEUTIC APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
HU178522B (en) * | 1979-04-11 | 1982-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing amino-isoquinoline derivatives |
WO1992002476A1 (en) | 1990-07-31 | 1992-02-20 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
NZ334613A (en) | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
JPH1087629A (en) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | New isoquinoline derivative, and its medicinal use |
EP1007525A1 (en) | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
HUP0204496A3 (en) | 2000-01-20 | 2004-07-28 | Eisai Co Ltd | Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (en) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
CN1441784A (en) * | 2000-07-12 | 2003-09-10 | 阿克佐诺贝尔公司 | Thrombin inhibitors comprising aminoisoquinoline group |
AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0101038D0 (en) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
EP1389194A2 (en) | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | Rho KINASE INHIBITORS |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
SE0104340D0 (en) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
WO2004009555A1 (en) * | 2002-07-22 | 2004-01-29 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
CN100383140C (en) | 2002-09-12 | 2008-04-23 | 麒麟麦酒株式会社 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
AU2004275720B2 (en) | 2003-09-23 | 2008-04-24 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
JP4718467B2 (en) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | Isoquinolinone potassium channel inhibitor |
US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
JP2005232175A (en) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | 5-substituted isoquinoline as medicine |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | Cadasil treatment with cholinesterase inhibitors |
SE0400850D0 (en) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
MX2008000956A (en) | 2005-07-26 | 2008-03-27 | Sanofi Aventis | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors. |
PT1910333E (en) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
PT2102164E (en) | 2006-12-27 | 2011-01-21 | Sanofi Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
BRPI0720909A2 (en) | 2006-12-27 | 2016-11-01 | Sanofi Aventis | substituted isoquinoline and isoquinolinone derivatives |
-
2007
- 2007-12-19 PT PT07856892T patent/PT2102164E/en unknown
- 2007-12-19 RU RU2009128652/04A patent/RU2468011C2/en not_active IP Right Cessation
- 2007-12-19 KR KR1020097013327A patent/KR101494452B1/en not_active IP Right Cessation
- 2007-12-19 WO PCT/EP2007/011169 patent/WO2008077556A1/en active Application Filing
- 2007-12-19 NZ NZ577984A patent/NZ577984A/en not_active IP Right Cessation
- 2007-12-19 JP JP2009543377A patent/JP5318779B2/en not_active Expired - Fee Related
- 2007-12-19 AU AU2007338412A patent/AU2007338412B2/en not_active Ceased
- 2007-12-19 PL PL07856892T patent/PL2102164T3/en unknown
- 2007-12-19 SI SI200730505T patent/SI2102164T1/en unknown
- 2007-12-19 CA CA2673922A patent/CA2673922C/en not_active Expired - Fee Related
- 2007-12-19 DE DE602007010981T patent/DE602007010981D1/en active Active
- 2007-12-19 BR BRPI0720859-6A patent/BRPI0720859A2/en not_active IP Right Cessation
- 2007-12-19 AT AT07856892T patent/ATE490243T1/en active
- 2007-12-19 ES ES07856892T patent/ES2355534T3/en active Active
- 2007-12-19 MY MYPI20092206A patent/MY154767A/en unknown
- 2007-12-19 DK DK07856892.0T patent/DK2102164T3/en active
- 2007-12-19 CN CN2007800484652A patent/CN101578266B/en not_active Expired - Fee Related
- 2007-12-19 RS RS20110096A patent/RS51655B/en unknown
- 2007-12-19 EP EP07856892A patent/EP2102164B1/en active Active
- 2007-12-19 MX MX2009005967A patent/MX2009005967A/en active IP Right Grant
- 2007-12-25 TW TW096149807A patent/TWI423803B/en not_active IP Right Cessation
- 2007-12-26 UY UY30845A patent/UY30845A1/en unknown
- 2007-12-26 CL CL200703820A patent/CL2007003820A1/en unknown
- 2007-12-26 AR ARP070105898A patent/AR064531A1/en unknown
-
2009
- 2009-05-20 CR CR10811A patent/CR10811A/en not_active Application Discontinuation
- 2009-05-22 ZA ZA200903555A patent/ZA200903555B/en unknown
- 2009-06-04 NI NI200900111A patent/NI200900111A/en unknown
- 2009-06-12 CO CO09061604A patent/CO6210815A2/en active IP Right Grant
- 2009-06-18 US US12/487,503 patent/US8710077B2/en not_active Expired - Fee Related
- 2009-06-23 SV SV2009003314A patent/SV2009003314A/en unknown
- 2009-06-24 MA MA32040A patent/MA31076B1/en unknown
- 2009-06-26 EC EC2009009468A patent/ECSP099468A/en unknown
- 2009-06-26 TN TNP2009000274A patent/TN2009000274A1/en unknown
- 2009-06-26 GT GT200900183A patent/GT200900183A/en unknown
- 2009-07-01 NO NO20092488A patent/NO20092488L/en not_active Application Discontinuation
-
2010
- 2010-04-29 HK HK10104257.8A patent/HK1138585A1/en not_active IP Right Cessation
- 2010-12-20 HR HR20100705T patent/HRP20100705T1/en unknown
-
2011
- 2011-02-04 CY CY20111100131T patent/CY1111323T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6210815A2 (en) | ISOQUINOLIN AND ISOQUINOLINONA DERIVATIVES REPLACED WITH CYCLLOKYLAMINE | |
CO6210690A2 (en) | NEW DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA REPLACED | |
AR054518A1 (en) | ISOQUINOLINE DERIVATIVES | |
MX2009004910A (en) | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h -pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto. | |
ES2604562T3 (en) | Nitric Oxide Donor Compounds | |
AR057082A1 (en) | CICLOHEXILAMINISOQUINOLONA DERIVATIVES | |
CO6210826A2 (en) | NEW DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA REPLACED | |
GT200300268A (en) | NEW HETEROCICLIC FLUOROGLUCOSID DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND THE USE OF THE SAME | |
AR067613A1 (en) | PK-DNA INHIBITORS, USE AND SYNTHESIS OF THE SAME | |
MY138941A (en) | Aryl-pyridine derivatives | |
AR064533A1 (en) | DERIVATIVES OF ISOQUINOLIN AND ISOQUINOLINONA SUBSTITUTED AND ITS USE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO THE INHIBITION OF RHO-QUINASA. | |
MX2009003129A (en) | Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties. | |
AR025739A1 (en) | NEW BENCIMIDAZOLON DERIVATIVES THAT HAVE AFFINITY FOR MIXED SEROTONINE AND DOPAMINE RECEIVERS | |
AR072281A1 (en) | ISOQUINOLINAS AND ISOQUINOLINONAS REPLACED | |
PA8783601A1 (en) | PIPERIDINE / PIPERAZINE DERIVATIVES | |
NO20083408L (en) | Corrosion inhibitors that have increased biodegradability and reduced toxicity | |
AR076880A1 (en) | PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE | |
WO2008061754A8 (en) | Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression | |
TW200722433A (en) | Phosphorus compounds, use thereof and flame retarding polyester fibers | |
CO4950561A1 (en) | ERGOLINE DERIVATIVES | |
GT200700084A (en) | DERIVATIVES OF INDANIL-PIPERAZINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
ATE548019T1 (en) | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | |
ECSP099506A (en) | DERIVATIVES OF 2-QUINOLINONA AND 2 QUINOXALINONA AND ITS USE AS ANTI BACTERIAL AGENTS | |
UY27980A1 (en) | INDOLES 2,7-REPLACED | |
UA94086C2 (en) | Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |